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Value in Health is a new journal. We, the Editor-in-Chief and the Scientific Editor, will assume
responsibility for guiding Value in Health (VH)
beginning with Volume 2 in 1999. Here we want
to introduce potential contributors and readers to
the kind of journal we want VH to be, and what
we want it to accomplish. These views are not yet
official policy. We welcome all reader comments
and criticisms. Feedback from the ISPOR member-
ship, officials, and the journal's own Editorial Ad-
visory Board will be brought together to establish
official Value in Health policies and procedures.
Both of us are trained in academic economics,
and though we have spent our careers in health
economics-and, in the past few years, pharrnaco-
economics-our backgrounds inescapably bias our
perceptions and convictions toward those of tradi-
tional economics. Insofar as this bias is unproduc-
tive, we will struggle with it. Our Editorial Advi-
sory Board, which includes many non-economists,
will undoubtedly assist in that effort. Of course,
we are also available to the ISPOR membership
through the usual routes of communication. We
will respond constructively to reasoned criticism
of our policies.
Second, we know that many other journals in-
vite and publish research in pharrnacoeconomics
and health outcomes analysis. Indeed, Value in
Health is a latecomer. The obvious question is
what will be unique about VH. VH hopes to in-
vest pharmacoeconornics and outcomes analysis
with 1) higher levels of rigor than existing journals
typically exhibit and 2) stronger theoretical bases
than they now possess. Reviews of published cost-
effectiveness analyses (CEAs), for example, have
concluded that many-perhaps the majority-of
them are methodologically deficient. We believe
that all research-not just that relating to CEA-
should be fully rigorous. Careful peer review will
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assure that work published in Value tn Health
meets this standard.
However, we think the problems of rigor and
theory are deeper than peer review alone can
solve. Pharmacoeconomics is still a new field, one
that has grown rapidly because its core subject,
CEA, is easy to apply and has powerful applica-
tions for healthcare decision-making in both the
public and private sectors. But CEA and pharrna-
coeconomics in general have developed with little
in the way of underlying theory. Obviously, CEA
is a mathematical tool, yet only several years ago
was it first pointed out that the so-called "prioritiza-
tion" form of the analysis-which was used, at least
in principle, in the initial formulation of the Oregon
Medicaid program [1]-is a particularly simple
application of linear programming [2]. Moreover,
the idea that CEA is an ordinary mathematical
optimization or quasi-optimization procedure (de-
pending on how it is rationalized), with all that
this implies for underlying theory and access to
computational methods such as nonlinear and sto-
chastic programming, has not been acted upon.
The crucial point is that a methodology or dis-
cipline weak in theory invites a casualness of ap-
proach, a lack of attention to detail, and a reliance
on ad hoc devices for deriving empirical results. A
sound underlying theory, conversely, always en-
hances the credibility of empirical findings and the
force of propositions for social policy. We think
the theoretical foundations of pharmacoeconom-
ics and health outcomes analysis are weak com-
pared with those in the related behavioral sci-
ences. Both fields stand to gain, and not just in
professional status, from the greater use of theory.
Though stressing the place of theory in phar-
rnacoeconomics and outcomes analysis, we do not
intend Value in Health to be predominantly a the-
oretical journal. We view it as a vehicle for trans-
lating theory into practice. That is, VH invites em-
pirical studies based on coherent logical or
quantitative models and theoretical studies having
significant practical or policy-related implications.
What VH will look for in manuscripts is not mere
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exercises in econometrics or psychometrics, but im-
portant ideas and empirical findings that, because
of the quality of their genesis and execution, will in-
fluence thinking in pharrnacoeconomics, outcomes
analysis, and the healthcare area as a whole.
The combination of pharmacoeconomics and
outcomes research in a single organization and
journal creates both opportunities and difficulties,
as people with very different backgrounds and re-
search perspectives interact and collaborate. Nev-
ertheless, obvious complementarities across the
fields exist. One cannot carry out meaningful
pharmacoeconomic research without knowing the
outcomes of medical interventions..Moreover,
pharmaceutical outcomes research, or health pol-
icy that ignores economic reality, is increasingly ir-
relevant to medical decision-making. We will now
sketch our views on both pharmacoeconomics and
outcomes research.
Pharmacoeconomics: Where We Are Now
It sometimes seems to us that pharmacoeconomics
is viewed only as, or primarily as, a collection of
techniques for evaluating pharmaceutical inter-
ventions in disease processes. The basic outcomes
data, health effects, and costs have been developed
and examined as much by researchers outside
pharmacoeconomics as by those in the field. Thus,
though it is presumptuous to say that research in
health effects, illness, and treatment costs "be-
longs" to pharmacoeconomists, the reality is that
evaluations of pharmaceutical interventions can-
not be performed without these kinds of outcomes
data. As a result, Value in Health welcomes theo-
retical and empirical papers on health effects and
health costs that further the foundations of phar-
macoeconomics andlor improve the quality and
reliability of evaluations of pharmaceutical inter-
ventions.
We also want to further the scope of pharrnaco-
economics. For Value in Health we shall define
pharmacoeconomics as the study of all behav-
ioral-, welfare-, andlor policy-related issues affect-
ing markets for drugs and pharmaceutical ser-
vices. Hence, VH hopes to attract interesting,
provocative, and worthy research not only from
pharmacoeconomists and economists, but from
behavioral psychologists, sociologists, clinicians,
ethicists, and others who have important things to
say about the actual or ideal structure, workings,
and performance of pharmaceutical markets.
Our overall interest in pharmacoeconomic issues
is motivated by two basic propositions we hold as
Hay and Ernst
axiomatic. The first is that the ultimate purpose of
healthcare is to increase the individual's-s-and thus
sociery's-e-health-related well-being. The second is
that a society's healrhcare resources ought to be al-
located in a way that maximizes total health-
related well-being, given the size, quality, and
technological state of the resource base. Value in
Health will be open to all original pharrnacoeco-
nomic studies bearing on these two propositions.
More specifically, what follows is a sampling of
subjects in which we would like to see new re-
search. In the following we use the term CEA
loosely to include, in addition to conventional cost
effectiveness analyses, also cost-utility analyses
(based on assigning a nonmonetary metric to the pa-
tient's or decision-maker's valuation of outcomes),
cost-consequences analyses (where the cost effects of
interventions are elicited and compartmentalized by
decision-maker perspective), cost-minimization anal-
yses (where differences in outcomes across interven-
tions can be legitimately ignored or disregarded),
and other comparative economic assessments. All of
these techniques are distinguished from cost-benefit
analyses (CBA) in which decisions to accept or reject
interventions are based on monetary assessments of
societal gains and losses.
• Empirical CEAs. Because CEA techniques are
now so widely known and used, studies pub-
lished in VH should be limited to three types: 1)
interventions with significant healthcare impact;
2) those of unique quality that can serve as
models of excellence for other researchers; and
3) those employing innovative methods applica-
ble as generalized techniques and thus improv-
ing overall CEA methodology.
• Methodological or theoretical CEA research, in-
cluding, but not restricted to, optimization tech-
niques, logical rationalizations of and methods
for real-world decision-making, and stochastic
methods.
• Empirical cost-benefit analyses (CBAs). The
method of CBA most often used in the medical
and pharmacoeconomic literature consists of es-
timating the total or societal cost of an illness
with and without the proposed intervention.
VH would like to publish new empirical CBAs
employing the compensation (willingness-to-
pay) principle standard in other economic appli-
cations of CBA, such as public project planning
and environmental policy.
• Economic evaluations of private and public pol-
icies, programs, or practices regarding the use
or supply of pharmaceutical goods and services,
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perhaps including medical practice guidelines,
private and government drug reimbursement pol-
icy, and/or private and government regulations
for drug or formulary approval. The evaluations
need not be formal CEAs or CBAs. Value in
Health is interested in data-based studies, but
will accept fact-based, logical arguments as well.
• Traditional empirical economic research on phar-
maceutical markets, most of which generally ap-
pears in economic journals. To make this research
and its methodology more accessibleto pharmaco-
economists, we hope to publish, at least occasion-
ally, original papers on drug pricing and marketing
behavior, consumers' drug demands or drug utili-
zation behavior, patterns of drug innovation and
diffusion, and other facets of the overall drug and
pharmaceutical-services markets. Value in Health
also encourages studies of the economic and
healthcare implications of trends in these markets.
Outcomes Research: Where We Are Now
Turning now to outcomes research, it is clear that
healthcare outcomes have different meanings for
different groups of people. The range of relevant
and valid healthcare outcomes spans the gamut
from clinical markers, to hard clinical end-points,
to patient- or clinician-reported health status and
quality of life, to death. The World Health Orga-
nization (WHO), now celebrating its 50th anni-
versary, defined health a half century ago as "a
state of complete physical, mental and social well-
being and not merely the absence of disease or
infirmity" (World Health Organization, http://www.
who.intJwh050/enlhealth4all.htm).
Outcomes measurement is the systematic, valid,
and reliable assessment of objective and subjective
domains of health status that are significant to pa-
tients, their families, and those with whom they in-
teract. But how should outcomes be measured? It is
our position that the principal benefit-related em-
pirical outcome of any healthcare intervention is
the number of quality-adjusted life-years (QALYs)
produced for patients. A QALY is self-evidently su-
perior to any other benefit-related outcome mea-
sure in current use. Moreover, if an efficient alloca-
tion of its healthcare resources is a society's goal,
then QALYs should be defined and measured iden-
tically for all diseases and other health problems. If
they are not, there is no way to tell how closely or
distantly society's allocation of healthcare resources
approaches an optimum. Accordingly, we consider
the standardized QALY the uniquely appropriate
outcome measure of healthcare benefits.
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This said, there remain many challenging em-
pirical and theoretical problems in the concept
and measurement of health-related quality of life
(QOL). Value in Health hopes to attract both in-
terest in these problems as well as new, creative ef-
forts to solve them. In particular, VH will wel-
come research that:
• Compares alternative instruments or methods
for measuring QOL. Because the conclusions of
empirical analyses and their policy implications
can vary with the choice of QOL instrument, it
is clearly desirable that pharrnacoeconomics
adopt a single method for assessing QOL. We
would like to see the development of standard
tests that can be applied to QOL instruments.
Some such tests do exist. VH invites research on
the development of standard tests for QOL in-
struments, and especially on innovative ways of
assessing content or construct validity.
• Compares measurements of QOL derived from
different instruments for different populations
classified by disease, symptom severity, or other
important features. Do all instruments seem to
capture QOL equally well over all populations?
• Compares common clinical measures of health
states or conditions with measures of QOL ob-
tained from standard instruments. Value in Health
is interested in research analyzing clinical out-
comes as predictors of QOL. If they are useful
predictors, they can be used as proxy indicators
of QOL when QOL cannot itself be directly esti-
mated. Otherwise, is there any plausible way of
assessing patient QOL in (for instance) interven-
tions such as short-term clinical trials?
• Examines the empirical properties of QOL mea-
sures, including their sampling distributions.
Value in Health would like to publish empirical
studies of QOL employing hard statistics, in-
cluding tests and adjustments for specification
errors.
• Yields new instruments for measuring QOL if
they can be shown to be superior those extant.
• Provides constructive insights into, or new
methods for estimating, willingness to pay for
improvements in QOL.
CEA methodology also offers opportunities for
health outcomes research. The conventional deci-
sion rule in pairwise comparisons of interventions
states that treatment A is more cost-effective than
treatment B if the incremental cost-effectiveness
ratio defined by the two treatments is less than a
certain critical value or cutoff point. This critical
value is the highest cost of producing a QALY
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over all healthcare interventions in current use.
Hence, in some intuitive sense, it is the highest
cost that society is currently willing to incur to
produce an additional year of quality-adjusted
life. Nevertheless, no rigorous rationale for this
crucial interpretation has ever been offered. The
fundamentals of CEA are therefore open to the
criticism that they are vague and unsubstantiated.
In economics, the price of any commodity is
understood to be determined by the interacting
forces of supply and demand. Can we consider the
pricing of QALYs and the setting of societal cutoff
points in a similar manner? The direct output of
the healthcare system is goods and services, yet it
is easy to think of these outputs as intermediate in-
puts in, say, the production of QALYs. The con-
cepts of investment in, the demand for, and the pro-
duction of health were proposed 25 years ago [3]
but have been little used since then. Do they never-
theless contain the building materials for a demand-
and-supply theory of the pricing of QALYs?
Seminal theoretical and empirical work on the
demand for years of life has appeared in the last
decade [4], and, although its usefulness has not
been clearly established, we would like to see more
of it. If such work does prove successful, a solid
theoretical foundation for CEA is on the way.
Other benefits, such as new methods for valuing
life and estimating willingness-to-pay for life years
(as consumers' surplus), would follow. We believe
that outcomes research should focus not only on
the measurement and estimation of QOL, but also
on why and how QALYs are valued by individuals
and society.
Cost Measurement
The notion of the costs of illnesses and treatments
is ordinarily regarded as elementary. We think
such a view is wrong. Not only are there many
misconceptions about the meaning of cost, but
there are also important differences of opinion
about this meaning among competent, sophisti-
cated researchers. The cost of any commodity is,
of course, an opportunity cost-the highest mar-
ket value of the commodity in any alternative use.
Opportunity cost varies with the perspective of the
cost analysis, but it should not be confused, as it
sometimes is, with willingness to pay for well-
being (as in the "costing" of years of life) or to
avoid the loss of well-being (as in the "costing" of
pain and suffering).
But more subtle difficulties than the miscon-
struing of willingness-to-pay for costs exist. One is
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the definition of the (indirect) opportunity cost of
work loss due to morbidity and premature death.
The foregone opportunity is usually defined as so-
ciety's consumption of the individual's labor prod-
uct, and is valued as his or her discounted labor
income over the duration of lost work time. In
particular, if one accepts the assertion that the
foregone opportunity due to morbidity or prema-
ture death is the loss of the individual's labor
product net of the resource usage required to keep
him or her alive and well, the cost of work loss
and premature death is still zero for the elderly
and permanently unemployed.
Supposing an intervention does prolong life,
how should the resources consumed by persons
who would have died without the intervention be
dealt with in cost analyses? It has long been ar-
gued that the cost of this resource use should be
added to the other costs of the intervention. The
argument, though generally ignored in empirical
analyses, survives. If the argument is accepted, it is
easy to think of examples, particularly for vaccina-
tion and other disease eradication programs in im-
poverished countries, in which it is much cheaper
for society to let people die than to save them. In
cost-of-illness studies, the societal cost of the illness
is ordinarily characterized as a "burden." But what
becomes of this burden if it is less costly to let pa-
tients die than save them, or if the indirect cost of
sickness and death in the elderly and unemployed
is zero?
Finally, differences of opinion regarding types
of illness costs that should and should not be in-
cluded in CEAs are common. One position holds
that including the (indirect) costs of lost labor
product due to morbidity and premature death
amounts to double counting because the effects of
the loss are already absorbed in QALYs. All the
same, the notion of opportunity cost is unambigu-
ous when the analytic perspective is fixed. How,
therefore, can it happen that a foregone opportu-
nity is given a positive value in cost-of-illness stud-
ies and a zero value in CEAs? For that matter,
how can it be said that the highest alternative mar-
ket valuation of a labor product can be repre-
sented as a number of QALYs when the units of
measurement are different?
We do not call for a massive investigation into
the meaning of cost in pharmacoeconomics and
outcomes analysis, but the kinds of difficulties we
mention here have nontrivial consequences for ap-
plied pharmacoeconomic research and the appli-
cation of this research in public policy. Nor are
methodological difficulties unique to the specifica-
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tion and estimation of costs. For this reason, we
want Value in Health to be an outlet for incisive
discussion and debate about the principles and
substance of pharrnacoeconomics and outcomes
research. For the present, we feel that the most
suitable vehicle is the critical literature review; as
the annual number of issues of Value in Health in-
creases, we hope to publish as many as several
such reviews each year. Reviews of methodology
and theory are welcomed, along with those of em-
pirical findings in special areas of healthcare or
policy interest. The latter should incorporate the
authors' assessments of the validity and implica-
tions of the research as well as descriptions or
summaries of results. We believe that thoughtful,
state-of-the-art reviews are helpful both in placing
bodies of research into clear focus and in building
usable structures of pharmacoeconomics and out-
comes analysis.
Methodological Standards and Guidelines
Critics point out that pharmacoeconomics and
outcomes research lack consensus regarding meth-
odological approaches, underlying theoretical par-
adigms, and presentation of results. Research in
the field is thus often viewed with skepticism re-
garding bias-or its appearance-in research
methods, results, and conclusions. A major goal of
Value in Health is to serve as a forum where con-
sensus can be built around development of guide-
lines for conduct and reporting of research in the
field.
We feel strongly about publishing articles on
the philosophical foundations of pharrnacoeco-
nomics and outcomes research. While these dis-
cussions can become too academic for much of the
journal's anticipated audience, if written well,
they can be thought-provoking and insightful.
Further, they are necessary for progress in devel-
oping methodological consensus.
The value of accepted methodology standards,
even when imperfect, far outweighs the confusion
and skepticism that exists when no standards are
agreed to at all. Until a more comprehensive set of
research guidelines is developed, we will encour-
age authors, to the extent possible, to utilize the
"Reference Case" methodology advocated in the
Russell et al. report on cost effectiveness guide-
lines for the US Public Health Service [5J. As more
researchers conform to these standards, journal
readers, research users, and healthcare decision-
makers will find it far easier to apply specific find-
ings to their own contexts, and to compare results
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from widely different medical interventions and
therapies.
Journal Format, Style, and Guidelines
Value in Health also plans to publish an invited ed-
itorial with each issue, and we will make space
available for selected letters or short comments on
Value in Health papers. At this point, the only re-
striction we will place on editorial content is that it
should be in keeping with the primary role of VH
as a research journal. Editorial content should deal
with public or private healthcare policy only inso-
far as policy is significantly influenced by findings
frorr pharrnacoeconomics and outcomes research.
We want to touch briefly on our position regard-
ing sponsored research. Value in Health will be
pleased to receive studies financially supported by
public and private sponsors. However, we will ask
contributors of sponsored studies to meet the usual
conflict-of-interest requirements, and we will ask
them to meet two additional requirements as well.
The first concerns data and models used in em-
pirical studies. We understand that sponsored re-
search often produces data that, on account of
cost or privileged nature, sponsors are reluctant to
make publicly available. We believe the impor-
tance of validation takes precedence over data
ownership rights. As a consequence, we will fol-
low the general policies of major medical and eco-
nomic journals, such as ]AMA and the American
Economic Reuieui, in requiring that all authors of
empirical research make their databases accessible
to referees or other persons we designate for ex-
amination or re-analysis of results. The use of pro-
prietary models and methodologies in empirical
research is less common, but we believe that re-
sults obtained, in effect, from "black boxes" do
not advance knowledge. Thus we will require that
all empirical models and methodologies be pre-
sented lucidly and in enough detail to make them
fully comprehensible to readers and accessible for
critical evaluation.
The second requirement we will ask authors to
meet bears on the content of sponsored research.
Sponsors sometimes regard the results of research
that they request and finance as proprietary. We
do not-and cannot-object to such a position
unless it affects researchers' decisions to publish.
We believe that all significant, competently de-
rived research findings deserve to be made known,
whether or not they advance a particular cause or
proprietary interest. We will therefore ask the con-
tributors of sponsored research to state that at no
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time did the sponsors impose conditions on the
contributors' plans or decisions to seek publication.
We realize that this policy cannot guarantee disin-
terested delivery of knowledge, but we hope it will
encourage impartiality by sponsors in their support
of pharmacoeconomic and outcomes research.
If Value in Health attracts the kind of research
we hope for, it has the potential for major conse-
quences on thought and policy in the healthcare
field.
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